Ipsogen
has developed a comprehensive range of quantitative
assays for AML; ALL and MPD1 including CML allowing a
sensitive and quantitative measurement of circulating
abnormal genes to monitor the treatment response and
disease evolution in leukemia patients. All Ipsogen
products are developed and manufactured in regulatory
compliant facilities and many are registered as CE
marked IVD2. In 2007 Ipsogen is applying for ISO 13485
accreditation. Our products are available today in over
40 countries thanks to a professional manufacturing and
marketing organization, and a reliable distribution
network.
Ipsogen R&D efforts are
based on internal research and international
collaborations. In Europe, Ipsogen is an active player
in collaborative networks such as EAC3, ELN4,
CONTICANET5 and COBRED6.
Janus Tyrosine Kinase
2
JAK2
JAK2 MutaQuant
™
Kit is a research tool
intended for the accurate quantification of
JAK2 mutant (V617F) and wild type alleles
and determination of allele load in human
genomic DNA.
Reference
Name
MQPP-01
JAK2 MutaQuant™
Kit
JAK2 MutaScreen™
Kits for V617F mutation screening
Kits
allow the detection and estimation of % JAK2
V617F mutation from genomic DNA isolated
from
whole peripheral human blood.
This test improves the classification of
Philadelphia Negative (Ph-)
myeloproliferative diseases.
Reference
Name
MSPP-01
JAK2 MutaScreen™
Kit
MSPP-02
JAK2 MutaScreen™
Mini Kit
MSPP-03
JAK2 MutaScreen™
Kit & Reference Scale
FusionQuant®,
Ipsogen
FusionQuant®
Kits are unique molecular kits providing
standardisation and accurate quantification
of fusion gene transcripts in Leukemia.
These ready to use kits contain primers &
probes mixes and standards specific for the
fusion gene and the ABL control gene. Most
of our kits are CE marked and can be used
for In Vitro Diagnostic use. CE marking of
the full FusionQuant®
Kits range will be completed soon.
FusionQuant®
Kits
As of December 7 2003,
all reagents used for the purpose of
diagnosis, monitoring or treatment of
disease must conform to the European in
vitro
diagnostic medical device
directive (98/79/EC).
The proof of compliance of such a product is
the CE mark. To comply with these new
regulations, Ipsogen now offers CE marked
FusionQuant®
Kits for monitoring therapy efficiency and
disease relapse.
Reference
Name
Cytogenetic Abnormality
FQPP-01
AML1-ETO
t(8;21)
FQPP-02
CBFb-MYH 11 A
Inv(16)
FQPP-05-CE*
PML-RAR bcr1
t(15;17)
FQPP-06
PML-RAR bcr2
t(15;17)
FQPP-07
PML-RAR bcr3
t(15;17)
FQPP-09-CE*
BCR-ABL e1a2 mbcr
t(9;22)
FQPP-09-ABL
BCR-ABL e1a2 mbcr
t(9;22)
FQPP-09-GUS
BCR-ABL e1a2 mbcr
t(9;22)
FQPP-09-BCR
BCR-ABL e1a2 mbcr
t(9;22)
FQPP-10-CE*
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-10-ABL
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-10-GUS
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-10-BCR
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-10M-CE* (Mega Kit)
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-10M-ABL (Mega Kit)
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-10M-GUS (Mega Kit)
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-10M-BCR (Mega Kit)
BCR-ABL b3a2 Mbcr
t(9;22)
FQPP-11
TEL – AML1 e4e11
t(12;21)
NPM1,
MutaQuant™
standards are intended to provide
calibration for the quantification of
individual single polymorphism by RQ-PCR and
are available for specific detection of
polymorphisms from both RNA (MQRS) and
genomic DNA (MQRS-G) samples.
Each MutaQuant™
Gene Standard is comprised of five vials
containing precisely controlled dilutions of
a given mutated gene to serve as a
calibrator for RQ-PCR.
